< Back to situations

[ORGANIZATION]

Eylea

Featured in 1 tracked story · first seen

Situations

[QUIET] [BUSINESS] [US] [FR] [IN]

Regeneron and Sanofi Q2 2026 financial performance

2 clusters · 2 sources · last updated

Latest: Sanofi reports strong Q2 2026 revenue growth driven by Dupixent

In the second quarter of 2026, both Regeneron Pharmaceuticals and Sanofi reported strong financial growth, largely attributed to the performance of the immunology drug Dupixent. Regeneron reported revenue of $4.29 billi